β-lactamases are important resistance factors to β-lactam antibiotics, especially in Gram-negative bacteria, that show an extraordinary diversity in terms of structure, mechanism of hydrolysis and substrate profile and susceptibility to inhibitors. Two families of β-lactamases are currently known: (a) the active site serine β-lactamases which perform hydrolysis of β-lactams via an acylation-deacylation mechanism and (b) the metallo-β-lactamases, which require one or two zinc ion(s) for activity. The current knowledge on β-lactamase structure-function relationships will be reviewed, with a particular focus on carbapenemases, such as KPC-2, VIM-2 and NDM-1 metallo-β-lactamases and OXA-type carbapenem-hydrolyzing enzymes, which currently represent among the most worrisome resistance determinants currently emerging in Pseudomonas aeruginosa, Acinetobacter baumannii and Enterobacteriaceae. The identification and development of new β-lactamase inhibitors, whose clinical need is stronger than ever, is an active field of research. The properties of novel β-lactamase inhibitors, some of which are under clinical development (e. g. NXL104), will be discussed.

Docquier, J.D. (2011). Clinically-relevant β-lactamases: Structure-function relationships and inhibition.. In European Journal of Microbiology and Immunology. Budapest : Akadémiai Kiadò.

Clinically-relevant β-lactamases: Structure-function relationships and inhibition.

DOCQUIER, JEAN DENIS
2011

Abstract

β-lactamases are important resistance factors to β-lactam antibiotics, especially in Gram-negative bacteria, that show an extraordinary diversity in terms of structure, mechanism of hydrolysis and substrate profile and susceptibility to inhibitors. Two families of β-lactamases are currently known: (a) the active site serine β-lactamases which perform hydrolysis of β-lactams via an acylation-deacylation mechanism and (b) the metallo-β-lactamases, which require one or two zinc ion(s) for activity. The current knowledge on β-lactamase structure-function relationships will be reviewed, with a particular focus on carbapenemases, such as KPC-2, VIM-2 and NDM-1 metallo-β-lactamases and OXA-type carbapenem-hydrolyzing enzymes, which currently represent among the most worrisome resistance determinants currently emerging in Pseudomonas aeruginosa, Acinetobacter baumannii and Enterobacteriaceae. The identification and development of new β-lactamase inhibitors, whose clinical need is stronger than ever, is an active field of research. The properties of novel β-lactamase inhibitors, some of which are under clinical development (e. g. NXL104), will be discussed.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11365/975415